ContraFect

ContraFect Goodwill

Goodwill of ContraFect (CFRXQ) as of Oct 19, 2026.

Goodwill

-USD

Last updated:

Goodwill of ContraFect is 2026 - USD. Goodwill of ContraFect was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

On Eulerpool you can find the complete historical development of Goodwill ContraFect since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's ContraFect historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ContraFect

All Key Metrics — ContraFect